fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
synthetic heparinoids 1236 104993-28-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fondaparinux
  • fondaparin
  • heparin pentasaccharide
  • fondaparinux sodium
  • arixtra
  • fondaparin sodium
Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.
  • Molecular weight: 1508.22
  • Formula: C31H53N3O49S8
  • CLOGP: -10.96
  • LIPINSKI: 3
  • HAC: 52
  • HDO: 19
  • TPSA: 805.48
  • ALOGS: -2.28
  • ROTB: 27

Drug dosage:

DoseUnitRoute
2.50 mg P

ADMET properties:

PropertyValueReference
CL (Clearance) 0.07 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.21 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 2001 FDA MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 624.50 18.54 228 9097 30282 50565517
Muscle haemorrhage 350.20 18.54 86 9239 2872 50592927
Pulmonary embolism 265.77 18.54 188 9137 101516 50494283
Anaemia 212.38 18.54 246 9079 252210 50343589
Shock haemorrhagic 176.38 18.54 64 9261 8280 50587519
Incorrect product administration duration 169.78 18.54 64 9261 9211 50586588
Cerebral haemorrhage 161.41 18.54 85 9240 26967 50568832
Heparin-induced thrombocytopenia 153.73 18.54 48 9277 3917 50591882
Deep vein thrombosis 136.82 18.54 111 9214 73193 50522606
Haemorrhage 128.30 18.54 94 9231 53347 50542452
Post procedural haemorrhage 125.24 18.54 48 9277 7222 50588577
Melaena 123.28 18.54 71 9254 26793 50569006
Haemoglobin decreased 120.21 18.54 132 9193 127084 50468715
Post procedural haematoma 117.08 18.54 30 9295 1190 50594609
Retroperitoneal haematoma 102.47 18.54 32 9293 2611 50593188
Intra-abdominal haematoma 100.59 18.54 28 9297 1529 50594270
Subdural haematoma 92.61 18.54 46 9279 12901 50582898
Subcutaneous haematoma 87.68 18.54 25 9300 1490 50594309
Incision site haematoma 76.20 18.54 13 9312 61 50595738
Thrombocytopenia 74.45 18.54 104 9221 127569 50468230
Abdominal wall haematoma 73.38 18.54 25 9300 2683 50593116
Compartment syndrome 72.68 18.54 23 9302 1959 50593840
Haematemesis 71.57 18.54 51 9274 27674 50568125
Haemorrhage subcutaneous 65.69 18.54 23 9302 2678 50593121
Blood loss anaemia 64.44 18.54 31 9294 8108 50587691
Thrombosis 61.60 18.54 63 9262 55770 50540029
Tooth erosion 52.78 18.54 13 9312 438 50595361
Extradural haematoma 52.37 18.54 17 9308 1570 50594229
Intra-abdominal haemorrhage 46.78 18.54 17 9308 2203 50593596
Incision site haemorrhage 46.65 18.54 12 9313 483 50595316
Fatigue 44.77 18.54 39 9286 707562 49888237
Pulpitis dental 40.47 18.54 12 9313 821 50594978
Thrombocytosis 39.45 18.54 19 9306 4977 50590822
Rectal haemorrhage 36.29 18.54 40 9285 38518 50557281
Skin necrosis 35.17 18.54 23 9302 10844 50584955
Cerebral haematoma 34.10 18.54 15 9310 3196 50592603
Haemoperitoneum 33.97 18.54 14 9311 2541 50593258
Gastrointestinal haemorrhage 33.04 18.54 53 9272 73268 50522531
Hypovolaemic shock 32.90 18.54 17 9308 5171 50590628
Abdominal wall haemorrhage 32.01 18.54 7 9318 138 50595661
Red blood cell count decreased 31.66 18.54 35 9290 33800 50561999
Intraventricular haemorrhage 30.96 18.54 12 9313 1858 50593941
Shock 29.74 18.54 27 9298 20623 50575176
Toxic skin eruption 29.72 18.54 21 9304 11230 50584569
Gastric haemorrhage 28.65 18.54 16 9309 5680 50590119
Splenic rupture 28.36 18.54 10 9315 1188 50594611
Periodontitis 28.33 18.54 13 9312 3056 50592743
Injection site haematoma 27.72 18.54 16 9309 6044 50589755
Hemiplegia 27.31 18.54 17 9308 7364 50588435
Venous thrombosis limb 27.04 18.54 12 9313 2610 50593189
Off label use 26.92 18.54 164 9161 474262 50121537
Wound haemorrhage 26.26 18.54 11 9314 2079 50593720
Haematocrit decreased 25.76 18.54 32 9293 34944 50560855
Drug interaction 25.69 18.54 88 9237 199533 50396266
Abdominal pain 25.22 18.54 98 9227 236130 50359669
Retroperitoneal haemorrhage 24.14 18.54 11 9314 2545 50593254
Toxicity to various agents 23.93 18.54 5 9320 212494 50383305
Hypoperfusion 23.68 18.54 9 9316 1321 50594478
Postoperative wound complication 23.46 18.54 8 9317 860 50594939
Prothrombin level decreased 23.16 18.54 7 9318 511 50595288
Abdominal discomfort 23.10 18.54 7 9318 231634 50364165
Spinal cord compression 23.08 18.54 12 9313 3697 50592102
Pain 23.04 18.54 45 9280 578858 50016941
Platelet count increased 22.90 18.54 20 9305 14520 50581279
Post procedural swelling 22.49 18.54 6 9319 279 50595520
Drug ineffective 22.43 18.54 77 9248 819256 49776543
Headache 22.27 18.54 37 9288 506498 50089301
Hepatic infarction 22.20 18.54 7 9318 589 50595210
Insomnia 22.15 18.54 3 9322 174862 50420937
Renal failure 21.33 18.54 55 9270 106578 50489221
Drug intolerance 21.17 18.54 7 9318 219097 50376702
Hepatic function abnormal 21.08 18.54 28 9297 32653 50563146
Drug hypersensitivity 21.01 18.54 10 9315 251000 50344799
Spontaneous haematoma 20.29 18.54 7 9318 779 50595020
Vulvovaginal injury 20.16 18.54 6 9319 416 50595383
Pelvic venous thrombosis 20.11 18.54 8 9317 1326 50594473
Traumatic haematoma 20.04 18.54 8 9317 1339 50594460
Pallor 20.00 18.54 23 9302 23176 50572623
Haemoptysis 19.80 18.54 24 9301 25549 50570250
Breast haematoma 19.59 18.54 5 9320 195 50595604
Brain herniation 19.23 18.54 10 9315 3082 50592717
Rash maculo-papular 19.02 18.54 24 9301 26617 50569182
Procedural haemorrhage 18.60 18.54 9 9316 2381 50593418
Weight increased 18.56 18.54 7 9318 201884 50393915

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 199.94 19.18 99 6431 23113 29544884
Incorrect product administration duration 197.89 19.18 61 6469 3980 29564017
Muscle haemorrhage 132.42 19.18 43 6487 3319 29564678
Heparin-induced thrombocytopenia 112.23 19.18 42 6488 4937 29563060
Pulmonary embolism 97.02 19.18 101 6429 76433 29491564
Haemorrhage 94.98 19.18 79 6451 44993 29523004
Anaemia 91.93 19.18 161 6369 200790 29367207
Cerebral haemorrhage 89.87 19.18 66 6464 31360 29536637
Shock haemorrhagic 79.93 19.18 40 6490 9511 29558486
Post procedural haemorrhage 67.51 19.18 33 6497 7458 29560539
Ureteric compression 62.25 19.18 13 6517 168 29567829
Post procedural haematoma 54.98 19.18 18 6512 1423 29566574
Haematoma muscle 53.46 19.18 16 6514 941 29567056
Melaena 52.23 19.18 48 6482 31128 29536869
Subdural haematoma 51.49 19.18 38 6492 18155 29549842
Deep vein thrombosis 46.14 19.18 60 6470 57339 29510658
Haematuria 44.95 19.18 52 6478 44087 29523910
Thrombocytosis 43.42 19.18 19 6511 3334 29564663
Haematemesis 41.40 19.18 38 6492 24588 29543409
Extradural haematoma 38.93 19.18 13 6517 1093 29566904
Pyelocaliectasis 38.89 19.18 13 6517 1096 29566901
Retroperitoneal haematoma 35.95 19.18 15 6515 2343 29565654
Retroperitoneal haemorrhage 34.97 19.18 15 6515 2508 29565489
Thrombosis 34.57 19.18 45 6485 43000 29524997
Intra-abdominal haematoma 34.19 19.18 12 6518 1172 29566825
Adrenal haemorrhage 33.68 19.18 8 6522 191 29567806
Haemoglobin decreased 32.54 19.18 73 6457 108302 29459695
Thrombocytopenia 32.09 19.18 83 6447 134740 29433257
Gastrointestinal haemorrhage 30.19 19.18 59 6471 79474 29488523
Spinal cord haemorrhage 29.96 19.18 8 6522 310 29567687
Abdominal wall haematoma 27.01 19.18 11 6519 1616 29566381
Altered state of consciousness 26.47 19.18 27 6503 19862 29548135
Venous thrombosis 26.04 19.18 13 6517 3069 29564928
Haemorrhage intracranial 23.58 19.18 22 6508 14520 29553477
Haemorrhagic stroke 23.07 19.18 15 6515 5841 29562156
Lumbosacral plexus injury 23.05 19.18 4 6526 17 29567980
Subacute cutaneous lupus erythematosus 22.13 19.18 8 6522 851 29567146
Cerebral haematoma 21.99 19.18 13 6517 4283 29563714
Haemarthrosis 21.27 19.18 11 6519 2795 29565202
Intra-abdominal haemorrhage 21.21 19.18 10 6520 2085 29565912
Coma 19.71 19.18 33 6497 39417 29528580
Haemothorax 19.18 19.18 11 6519 3425 29564572

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematoma 603.03 17.29 252 12099 45998 64440383
Muscle haemorrhage 294.51 17.29 87 12264 5666 64480715
Pulmonary embolism 277.48 17.29 227 12124 146129 64340252
Heparin-induced thrombocytopenia 233.66 17.29 80 12271 8399 64477982
Incorrect product administration duration 222.66 17.29 80 12271 9678 64476703
Cerebral haemorrhage 219.26 17.29 131 12220 50959 64435422
Anaemia 206.42 17.29 304 12047 378376 64108005
Shock haemorrhagic 180.58 17.29 80 12271 16711 64469670
Haemorrhage 156.22 17.29 126 12225 79225 64407156
Deep vein thrombosis 148.28 17.29 138 12213 105044 64381337
Post procedural haemorrhage 123.35 17.29 56 12295 12375 64474006
Post procedural haematoma 118.66 17.29 35 12316 2263 64484118
Melaena 118.19 17.29 91 12260 53457 64432924
Haematemesis 95.33 17.29 76 12275 46923 64439458
Subdural haematoma 90.28 17.29 60 12291 27994 64458387
Retroperitoneal haematoma 83.14 17.29 32 12319 4679 64481702
Thrombosis 83.12 17.29 84 12267 70558 64415823
Intra-abdominal haematoma 78.58 17.29 26 12325 2453 64483928
Haemoglobin decreased 73.63 17.29 133 12218 194930 64291451
Extradural haematoma 72.72 17.29 25 12326 2651 64483730
Abdominal wall haematoma 71.56 17.29 28 12323 4277 64482104
Subcutaneous haematoma 70.61 17.29 24 12327 2459 64483922
Thrombocytopenia 70.17 17.29 141 12210 223660 64262721
Ureteric compression 63.95 17.29 13 12338 170 64486211
Blood loss anaemia 63.11 17.29 37 12314 13855 64472526
Thrombocytosis 60.92 17.29 29 12322 7127 64479254
Haematuria 55.40 17.29 63 12288 60408 64425973
Haematoma muscle 53.63 17.29 18 12333 1775 64484606
Pyelocaliectasis 53.24 17.29 15 12336 823 64485558
Incision site haemorrhage 51.10 17.29 15 12336 953 64485428
Toxicity to various agents 49.07 17.29 6 12345 363507 64122874
Tooth erosion 48.88 17.29 12 12339 383 64485998
Compartment syndrome 44.95 17.29 20 12331 4212 64482169
Fatigue 40.01 17.29 51 12300 748679 63737702
Skin necrosis 39.81 17.29 28 12323 14301 64472080
Brain herniation 39.50 17.29 21 12330 6512 64479869
Haemorrhage subcutaneous 38.12 17.29 18 12333 4343 64482038
Pulpitis dental 37.63 17.29 12 12339 1007 64485374
Off label use 37.12 17.29 227 12124 632579 63853802
Drug interaction 36.92 17.29 152 12199 361931 64124450
Injection site haematoma 36.74 17.29 17 12334 3919 64482462
Gastric haemorrhage 36.66 17.29 26 12325 13455 64472926
Retroperitoneal haemorrhage 36.24 17.29 18 12333 4850 64481531
Spinal cord haemorrhage 35.92 17.29 10 12341 525 64485856
Adrenal haemorrhage 35.39 17.29 10 12341 554 64485827
Gastrointestinal haemorrhage 34.04 17.29 77 12274 132235 64354146
Altered state of consciousness 33.88 17.29 39 12312 37863 64448518
Wound haemorrhage 32.59 17.29 15 12336 3416 64482965
Incision site haematoma 31.84 17.29 7 12344 136 64486245
Rectal haemorrhage 31.09 17.29 48 12303 61769 64424612
Haemorrhage intracranial 31.03 17.29 30 12321 23854 64462527
Haemothorax 30.51 17.29 16 12335 4826 64481555
Toxic skin eruption 28.46 17.29 26 12325 19258 64467123
Hypovolaemic shock 28.38 17.29 20 12331 10246 64476135
Haemoperitoneum 27.74 17.29 14 12337 3901 64482480
Nasopharyngitis 27.01 17.29 3 12348 196070 64290311
Coma 25.96 17.29 54 12297 87561 64398820
Venous thrombosis limb 25.09 17.29 13 12338 3824 64482557
Haemorrhagic stroke 24.34 17.29 18 12333 9933 64476448
Eosinophilia 24.14 17.29 33 12318 38043 64448338
Venous thrombosis 23.84 17.29 15 12336 6366 64480015
Lumbosacral plexus injury 23.61 17.29 4 12347 17 64486364
Abdominal pain 23.51 17.29 120 12231 312255 64174126
Weight increased 23.39 17.29 6 12345 213342 64273039
Drug intolerance 23.25 17.29 4 12347 187988 64298393
Periodontitis 21.35 17.29 12 12339 4147 64482234
Haemarthrosis 21.33 17.29 13 12338 5216 64481165
Cross sensitivity reaction 20.85 17.29 11 12340 3356 64483025
Spinal cord compression 20.30 17.29 13 12338 5690 64480691
Cough 20.11 17.29 17 12334 302131 64184250
Hepatic infarction 19.79 17.29 7 12344 807 64485574
Postoperative wound complication 19.34 17.29 8 12343 1410 64484971
Acute coronary syndrome 19.18 17.29 21 12330 19289 64467092
Haemoptysis 19.16 17.29 34 12317 49014 64437367
Insomnia 19.10 17.29 7 12344 197829 64288552
Electrocardiogram QT prolonged 19.05 17.29 45 12306 79403 64406978
Intra-abdominal haemorrhage 19.00 17.29 11 12340 4020 64482361
Drug hypersensitivity 18.96 17.29 11 12340 237804 64248577
Rash maculo-papular 18.89 17.29 33 12318 46993 64439388
Intraventricular haemorrhage 18.70 17.29 11 12340 4142 64482239
Brain stem haemorrhage 18.65 17.29 8 12343 1543 64484838
Pain 18.55 17.29 50 12301 553461 63932920
Hypoperfusion 18.43 17.29 9 12342 2337 64484044
Hemiplegia 18.42 17.29 17 12334 12751 64473630
Vulvovaginal injury 18.04 17.29 5 12346 258 64486123
Platelet count increased 18.00 17.29 20 12331 18676 64467705
Intracranial pressure increased 17.90 17.29 13 12338 6976 64479405
Cerebellar haematoma 17.90 17.29 6 12345 589 64485792
Cerebral haematoma 17.58 17.29 13 12338 7172 64479209

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX05 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065427 Factor Xa Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA MoA N0000175635 Factor Xa Inhibitors
FDA EPC N0000175637 Factor Xa Inhibitor
CHEBI has role CHEBI:50249 anticoagulants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Deep venous thrombosis indication 128053003
Pulmonary thromboembolism indication 233935004
Prevention of deep vein thrombosis indication 439993001
Myocardial infarction off-label use 22298006 DOID:5844
Acute coronary syndrome off-label use 394659003
Diabetic retinopathy contraindication 4855003 DOID:8947
Gastrointestinal ulcer contraindication 40845000
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Operation on brain contraindication 70586009
Heparin-induced thrombocytopenia contraindication 73397007
Kidney disease contraindication 90708001 DOID:557
Autoimmune thrombocytopenia contraindication 128091003
Hemorrhagic cerebral infarction contraindication 230706003
Local anesthetic intrathecal block contraindication 231249005
Procedure on spine contraindication 238181003
Anemia contraindication 271737000 DOID:2355
Lumbar puncture contraindication 277762005
Bacterial endocarditis contraindication 301183007
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure on eye proper contraindication 373353005
Hypertensive urgency contraindication 443482000
Significant Bleeding contraindication
Platelet Aggregation Inhibition contraindication
Placement of Epidural Catheter contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.23 acidic
pKa2 0.94 acidic
pKa3 2.46 acidic
pKa4 3.08 acidic
pKa5 11.49 acidic
pKa6 11.98 acidic
pKa7 12.26 acidic
pKa8 12.43 acidic
pKa9 12.91 acidic
pKa10 13.69 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Antithrombin-III Secreted ACTIVATOR Kd 7.49 IUPHAR CHEMBL

External reference:

IDSource
4021296 VUID
N0000148733 NUI
D01844 KEGG_DRUG
114870-03-0 SECONDARY_CAS_RN
4021296 VANDF
C1098510 UMLSCUI
CHEBI:61033 CHEBI
NTO PDB_CHEM_ID
CHEMBL1201202 ChEMBL_ID
CHEMBL1276258 ChEMBL_ID
CHEMBL1200644 ChEMBL_ID
D000077425 MESH_DESCRIPTOR_UI
DB00569 DRUGBANK_ID
C049714 MESH_SUPPLEMENTAL_RECORD_UI
6819 IUPHAR_LIGAND_ID
J177FOW5JL UNII
5282448 PUBCHEM_CID
321208 RXNORM
16268 MMSL
184641 MMSL
18938 MMSL
42652 MMSL
d04786 MMSL
009549 NDDF
009550 NDDF
385517000 SNOMEDCT_US
395236007 SNOMEDCT_US
708189008 SNOMEDCT_US
7653 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3443 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3454 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3465 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-3476 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-154 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-155 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-156 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
fondaparinux sodium HUMAN PRESCRIPTION DRUG LABEL 1 11797-157 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-606 INJECTION 10 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-607 INJECTION 2.50 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-608 INJECTION 5 mg SUBCUTANEOUS ANDA 26 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43598-609 INJECTION 7.50 mg SUBCUTANEOUS ANDA 26 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5501 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 27 sections
ARIXTRA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5652 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-678 INJECTION 2.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-679 INJECTION 5 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-680 INJECTION 7.50 mg SUBCUTANEOUS ANDA 27 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-681 INJECTION 10 mg SUBCUTANEOUS ANDA 27 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-230 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-231 INJECTION, SOLUTION 5 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-232 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS ANDA 28 sections
FONDAPARINUX SODIUM Human Prescription Drug Label 1 55150-233 INJECTION, SOLUTION 10 mg SUBCUTANEOUS ANDA 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-582 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-583 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-584 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA authorized generic 28 sections
Fondaparinux Sodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-585 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA authorized generic 28 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-592 INJECTION, SOLUTION 2.50 mg SUBCUTANEOUS NDA 28 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-593 INJECTION, SOLUTION 5 mg SUBCUTANEOUS NDA 28 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-594 INJECTION, SOLUTION 7.50 mg SUBCUTANEOUS NDA 28 sections
Arixtra HUMAN PRESCRIPTION DRUG LABEL 1 67457-595 INJECTION, SOLUTION 10 mg SUBCUTANEOUS NDA 28 sections